Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIntelgenx Technologs

Intelgenx Technologs

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None CAD 0.00(0%)
Last update at 2024-07-16T16:00:11.479999Z
Market Cap
37.69M

Momentum Score

…

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.14
Low
0.35
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.24
Dividend Yield
-
Revenue TTM
0.79M
Revenue Per Share
0.01
Gross Profit TTM
-0.91M
Debt / Equity
-3.07
ROE
-4772.32%
Net Debt
9.30M
ROCE
-138.04%
Diluted EPS TTM
-0.08

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -10.69M -9.32M -7.04M -10.66M -10.11M
Net income -10.69M -9.31M -7.04M -10.66M -10.11M
Selling general administrative 4.70M 3.75M 4.44M 5.80M 5.00M
Gross profit -0.91M -0.72M 1.54M 0.74M 1.82M
Reconciled depreciation 0.78M 0.79M 0.73M 0.72M 0.72M
Ebit -9.41M -7.83M -5.84M -9.45M -8.99M
Ebitda -8.63M -7.04M -5.11M -8.73M -8.27M
Depreciation and amortization 0.78M 0.79M 0.73M 0.72M 0.72M
Operating income -9.41M -7.98M -6.26M -9.55M -9.00M
Other operating expenses 10.36M 9.52M 7.81M 10.29M 10.82M
Interest expense 1.28M 1.49M 1.20M 1.21M 1.12M
Tax provision 0.00M -0.01M 0.00M 0.00M 0.00M
Interest income 1.28M 0.15M 0.78M 1.11M 1.11M
Net interest income -1.28M -1.34M -0.78M -1.11M -1.11M
Income tax expense 0.00M -0.01M 0.42M 0.10M 0.01M
Total revenue 0.95M 1.53M 1.54M 0.74M 1.82M
Total operating expenses 8.51M 7.26M 7.81M 10.29M 10.82M
Cost of revenue 1.86M 2.26M - - 0.00M
Total other income expense net -1.28M -1.34M -0.78M -1.11M -1.11M
Net income from continuing ops -10.69M -9.31M -7.04M -10.66M -10.11M
Net income applicable to common shares -10.69M -9.31M -7.04M -10.66M -10.11M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 9.19M 17.91M 11.12M 11.02M 20.02M
Other current assets 0.33M 0.31M 0.57M 0.17M 0.46M
Total liab 12.61M 14.03M 12.07M 10.73M 10.03M
Total stockholder equity -3.42M 3.87M -0.95M 0.29M 9.99M
Other current liab 2.10M 2.30M 1.99M 1.94M -
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -68.53M -57.86M -48.55M -41.51M -30.90M
Other liab - 0.08M - - 0.05M
Other assets 0.24M 0.25M 0.25M 0.75M 0.71M
Cash 1.21M 3.94M 1.21M 1.33M 6.82M
Cash and equivalents - 3.94M 1.21M 1.33M 6.82M
Total current liabilities 2.37M 7.02M 4.37M 8.45M 2.72M
Current deferred revenue - 0.19M 0.17M - -
Net debt 9.30M 7.52M 8.71M 7.45M 1.14M
Short term debt 0.27M 4.53M 2.21M 6.51M 0.69M
Short long term debt - 4.25M 2.05M 6.37M 0.69M
Short long term debt total 10.51M 11.47M 9.92M 8.79M 7.95M
Other stockholder equity 67.34M 63.10M 48.45M 42.63M 42.05M
Property plant equipment 5.16M 6.22M 6.56M 7.05M 6.25M
Total current assets 3.79M 11.44M 4.30M 3.22M 13.06M
Net tangible assets -3.42M 3.87M -0.95M 0.29M 9.99M
Short term investments 1.32M 6.00M 1.04M 0.58M 4.18M
Net receivables 0.87M 1.12M 1.25M 0.76M 1.23M
Long term debt 9.77M 6.21M 7.14M 1.73M 7.26M
Inventory 0.06M 0.06M 0.24M 0.38M 0.38M
Accounts payable 2.10M 2.30M 1.99M 1.94M 2.03M
Accumulated other comprehensive income -2.23M -1.37M -0.86M -0.84M -1.17M
Non currrent assets other 0.24M 0.25M 0.25M 0.75M 0.71M
Non current assets total 5.40M 6.47M 6.81M 7.80M 6.96M
Capital lease obligations 0.74M 1.01M 0.73M 0.69M -
Long term debt total 9.81M 6.29M 7.22M 1.73M 7.26M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 3.51M -4.97M -0.41M 3.73M -1.08M
Change to liabilities -0.26M 0.31M 0.10M -0.16M 0.56M
Total cashflows from investing activities 3.51M -5.07M -0.53M 3.21M -2.18M
Net borrowings - 3.63M 1.13M -0.71M -0.75M
Total cash from financing activities 2.96M 15.49M 6.24M -0.69M 16.40M
Change to operating activities -0.04M 0.26M 0.12M 0.29M -0.27M
Net income -10.69M -9.31M -7.04M -10.66M -10.11M
Change in cash -2.73M 2.74M -0.13M -5.48M 5.22M
Begin period cash flow 3.94M 1.21M 1.33M 6.82M 1.59M
End period cash flow 1.21M 3.94M 1.21M 1.33M 6.82M
Total cash from operating activities -9.52M -7.17M -5.77M -8.20M -8.53M
Issuance of capital stock 0.00M 12.35M 5.56M 0.00M 15.41M
Depreciation 0.78M 0.79M 0.73M 0.72M 0.72M
Other cashflows from investing activities 3.78M -4.97M -0.41M 3.73M -1.08M
Change to inventory 0.00M 0.18M 0.14M 0.14M -0.38M
Change to account receivables -0.03M -0.42M 0.12M 0.43M -0.19M
Sale purchase of stock 0.00M 12.35M 5.56M 0.02M 17.74M
Other cashflows from financing activities 3.00M 3.91M 1.15M 0.02M 1.74M
Change to netincome 0.45M 0.66M 0.42M 1.19M 1.14M
Capital expenditures 0.27M 0.11M 0.12M 0.53M 1.10M
Change in working capital -0.05M 0.69M 0.12M 0.56M -0.28M
Stock based compensation 0.11M 0.11M 0.19M 0.33M 0.37M
Other non cash items 0.34M 0.56M 0.23M 0.85M 0.77M
Free cash flow -9.79M -7.28M -5.89M -8.72M -9.63M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EPRX
Eupraxia Pharmaceuticals Inc		 0.03
0.31%		 9.68 - - - 8.45 - -3.88
FRX
Fennec Pharmaceuticals Inc		 0.20
1.35%		 14.99 - 21.01 6.95 6.35 4.25 20.27
MSCL
Satellos Bioscience Inc.		 -
-%		 9.00 - - - 5.85 - 6.47
HBP
Helix BioPharma Corp.		 -0.10
9.80%		 0.92 - 3.87 4263.36 9.74 4422.35 -6.36

Profile*

Intelgenx Technologs

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.

6420 Abrams, Montreal, QC, Canada, H4S 1Y2

514 331 7440

https://www.intelgenx.com

Name Title Year Born
Dr. Horst G. Zerbe Ph.D. Chairman, CEO & Chairman of Scientific Advisory Board 1947
Mr. André Godin C.A., CPA, CA, CPA Pres & CFO 1964
Mr. Tommy Kenny J.D., L.L.B., M.Sc. VP of Intellectual Property & Legal Affairs and Gen. Counsel 1987
Ms. Nadine Paiement Vice-Chair of Scientific Advisory Board and VP of R&D - IntelGenx Corp 1977
Stephen Kilmer Investor Relations Officer NA
Ms. Ingrid Zerbe Corp. Sec. 1954

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.34
+14.45%
OMG
CAD 1.70
+13.76%
ARTG
CAD 39.54
+12.59%
DSV
CAD 10.83
+12.58%
TLRY
CAD 4.17
+12.10%
DRUG
CAD 25.95
-30.02%
HUT
CAD 69.16
-22.20%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.70
-15.62%
VET
CAD 15.04
-13.31%

Equity Sectors*

  • Basic Materials

    +4.80%

  • Communication Services

    +2.78%

  • Consumer Cyclical

    +2.82%

  • Consumer Defensive

    +0.74%

  • Energy

    -4.92%

  • Financial Services

    +2.47%

  • Healthcare

    -0.30%

  • Industrials

    -0.38%

  • Real Estate

    +1.75%

  • Technology

    +0.82%

  • Utilities

    +1.29%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…